TGFBR1 and cancer: Several ALK5 inhibitors are currently at pre-clinical and clinical stages for various cancers including melanoma (Akhurst & Hata, 2012; Flavell et al, 2010; Hawinkels & ten Dijke, 2011; Mohammad et al, 2011).